MiNK Therapeutics (NASDAQ:INKT) Trading Down 1.8% – Should You Sell?

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares fell 1.8% during mid-day trading on Wednesday . The company traded as low as $0.64 and last traded at $0.65. 25,556 shares traded hands during trading, a decline of 70% from the average session volume of 86,186 shares. The stock had previously closed at $0.66.

Analyst Ratings Changes

A number of research firms have issued reports on INKT. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of MiNK Therapeutics in a research report on Friday, November 15th. Robert W. Baird cut their target price on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 15th.

MiNK Therapeutics Trading Down 2.2 %

The stock has a market capitalization of $24.36 million, a PE ratio of -1.58 and a beta of 0.10. The firm’s fifty day moving average price is $0.71 and its two-hundred day moving average price is $0.81.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC grew its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.